Clinical trial NCT04428775: A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
Official title: A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Amyotrophic Lateral Sclerosis
Keywords: ALS
Amyotrophic Lateral Sclerosis
Lou Gehrig's disease
mild ALS
moderate ALS
mild to moderate ALS
Lead sponsor: AZTherapies, Inc.
Sponsor class: INDUSTRY
First posted: 2020-06-11
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two doses of ALZT-OP1a (cromolyn) are being evaluated in this study. Each dose of ALZT-OP1a (cromolyn) will be co-administered with a stable dose of ALS standard-of-care treatment as prescribed by their physician.
Primary purpose: BASIC_SCIENCE

Brief summary: This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.

Detailed description: This Phase IIa study is designed as a randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The study will evaluate 1) safety, 2) tolerability, 3) changes in physical function measured using the ALSFRS-R, 4) two doses of ALZT-OP1a in order to determine an optimal and effective dose that could positively impact neuro-inflammatory biomarkers, and 5) to demonstrate preliminary evidence if this treatment could potentially slow down or arrest functional decline in subjects with mild to moderate ALS.

Up to 80 evaluable subjects will be randomly assigned to one of two treatment groups: Group I (n=40) will consist of low dose ALZT-OP1a, administered via dry powder inhalation; OR Group II (n=40), which will consist of high dose ALZT-OP1a, administered via dry powder inhaler.

Subjects will dose for 12 weeks and will be asked to return to the site for scheduled visits and biomarker collection at Week 4, Week 8, and Week 12.

Eligibility criteria: Inclusion Criteria:

* Male or female subjects aged 18-75 years, both inclusive;
* Must provide written informed consent before any study related procedures;
* Should be capable to complete all trial related procedures, assessments and visits in the judgement of Investigator;
* Familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria;
* Disease duration from ALS diagnosis ≤24 months;
* ALSFRS-R total score ≥ 36 at screening visit;
* ALSFRS-R Breathing sub-score should be ≥9 at the time of screening;
* ALSFRS-R Bulbar sub-score should be ≥9 at the time of screening;
* Peak inspiratory flow rate (PIFR) ≥ 100 L/minute;
* Forced vital capacity (FVC) \>70% of predicted value;
* Participant must be receiving treatment with stable dose of standard of care treatment for ≥30 days prior to signing informed consent.

Exclusion Criteria:

* Subjects with bulbar-onset ALS;
* Any use of non-invasive ventilation (e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation;
* Any other significant neurological disorder which can interfere with study assessments, e.g., significant cognitive impairment and/or clinical dementia;
* Significant psychiatric illness like schizophrenia, bipolar disorder etc. Subjects with depression can be included, only if the depression has been stable and no episode of major depression has occurred in past one year;
* Severe cardiac disease (e.g.,corrected QT interval \> 500ms), Torsade de Pointes, evidence of significant heart failure (New York Heart Association \[NYHA\] Class 3 or greater, myocardial infarction or unstable angina in the 6 months prior to screening);
* Any moderate-to-severe pulmonary disease or difficulty taking inhaled drugs;
* Inability to tolerate the administration of an oral inhaled powder via dry powder inhaler (DPI);
* Has taken any investigational study drug within 30 days or five half-lives of the drug, whichever is longer, prior to dosing;
* Currently taking cromolyn, or has taken cromolyn, within the past 12 months;
* Allergy to cromolyn or cromolyn products, such as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.;
* Taking inhaled protein products on a chronic basis (such as insulin, parathyroid hormone \[PTH\], etc.);
* Subjects who weigh 88 lb (40 kg) or less, or, body mass index (BMI) of \<17.5 or \>35.0 at screening;
* Moderate-to-severe liver disease: aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin concentrations \>3 times the upper limit of normal; patients with hepatic diseases such as hepatic cirrhosis, hepatic cancer and active hepatitis
* Moderate-to-severe renal disease: creatinine clearance \<45 mL/min/1.73 m2 (by Cockcroft-Gault calculation);
* Any clinically significant disorder or laboratory abnormality that, in the investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of the study results;
* Pregnant or breast-feeding females or sexually active females with childbearing potential, if no adequate contraceptive measures are used.

Primary outcomes:
measure: Plasma Biomarkers
timeFrame: up to 12 weeks
Secondary outcomes:
measure: Changes from baseline in ALS disease progression
timeFrame: up to 12 weeks
measure: Time to Event Requiring Respiratory Support
timeFrame: up to 12 weeks
measure: Changes from baseline in pulmonary function (forced vital capacity)
timeFrame: up to 12 weeks
measure: Changes from baseline in pulmonary function (peak inspiratory flow rate)
timeFrame: up to 12 weeks
measure: Incidence of adverse event (tolerability) related to ALZT-OP1a
timeFrame: up to 12 weeks
measure: Number of participants with abnormal vital signs
timeFrame: up to 12 weeks
measure: Number of participants with abnormal physical or neurological examinations
timeFrame: up to 12 weeks
measure: Number of participants with abnormal electrocardiograms (ECGs)
timeFrame: up to 12 weeks
measure: Number of participants with treatment emergent clinically significant laboratory assessments
timeFrame: up to 12 weeks
measure: Changes from baseline in suicidal ideation and behavior
timeFrame: up to 12 weeks
measure: The number of study dropouts due to serious, unanticipated treatment emergent adverse events
timeFrame: up to 12 weeks
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD Altman Clinical and Translational Research Institute
state: California
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Winston-Salem
country: United States
facility: Wake Forest School of Medicine
state: North Carolina
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: AZTherapies, Inc.
name: David R. Elmaleh, PhD
role: STUDY_DIRECTOR
References:
citation: Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, Cudkowicz ME, Tanzi RE, Sadri-Vakili G. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. doi: 10.1038/s41598-019-53982-w.